Psilocybin in Bipolar Disorder

https://journals.sagepub.com/doi/pdf/10.1177/02698811221131997

Study Design and Participants

Data Collection and Ethical Approval

• The study, conducted from October 2020 to January 2021, received ethical approval from the Institutional Review Board of the University of California, San Francisco. Data confidentiality was maintained, and participants provided written consent before proceeding.

Inclusion and Recruitment

• Participants had to be 18 years of age or older, have a self-reported diagnosis of bipolar disorder, and have used psilocybin to achieve a full psychedelic trip. Recruitment efforts targeted demographically diverse groups through various online channels and social media platforms.

Measurement and Data Analysis

• An online survey, developed with the contribution of individuals with bipolar disorder, included questions about demographics, intentions to use psilocybin, experiences of adverse events, and mental health history. Data collection occurred through the Qualtrics research platform, and multiple responses from the same IP address were investigated for duplicate responses.

Limitations and Future Phases

• This study represents the initial phase of a sequential mixed-methods project aimed at improving understanding of psilocybin use and its outcomes among people with bipolar disorder. The second phase will involve qualitative interviews with a subset of respondents, informing the design of an open-label dose-escalation study.

Experiences with the Use of Psilocybin

Positive Experiences

• A large proportion of respondents reported positive experiences with psilocybin, citing psychological growth, new perspectives, and self-compassion. Many considered the benefits to outweigh any challenging aspects, indicating personal growth and improved coping skills.

Negative Experiences

• A smaller number of respondents described exclusively negative experiences, including anxiety, psychosis-like phenomena, and mood symptoms. Some attributed these experiences to adjustment and environmental factors, highlighting the need for further investigation.

Qualitative Analysis

• The content analysis of the qualitative data revealed gaps in the quantitative elements of the research, emphasizing the importance of understanding both positive and negative experiences with psilocybin use.

Implications for Treatment

• The results suggest the need for further investigations into psilocybin-based treatments for bipolar disorder, focusing on careful symptom monitoring. Limitations of the study, including the use of online surveys for data collection, were acknowledged.

Implications and Future Directions

Clinical Implications

• The study's findings have implications for the design of future clinical trials and the development of treatment protocols involving psilocybin for individuals with bipolar disorder.

Politics and Research

• The study highlights the need for policy considerations and further research into the safety and efficacy of psilocybin-based treatments for bipolar disorder, addressing the limitations of the initial phase of research.

Ethical Considerations

• Ethical considerations in the use of psilocybin for mental health treatment, including participant safety and informed consent, are crucial aspects that require careful attention in future research and clinical practice.

Future Directions

• The study paves the way for future research, including qualitative interviews with a subset of respondents and the design of an open-label dose-escalation study. The results will inform ongoing research into psilocybin therapy for bipolar disorder.

• Journal of Psychopharmacology